The Scientific World Journal

The Scientific World Journal / 2011 / Article

Review Article | Open Access

Volume 11 |Article ID 680784 | https://doi.org/10.1100/tsw.2011.10

Arvind Chhabra, "TCR-Engineered, Customized, Antitumor T Cells for Cancer Immunotherapy: Advantages and Limitations", The Scientific World Journal, vol. 11, Article ID 680784, 9 pages, 2011. https://doi.org/10.1100/tsw.2011.10

TCR-Engineered, Customized, Antitumor T Cells for Cancer Immunotherapy: Advantages and Limitations

Academic Editor: Marc Lippman
Received28 Aug 2010
Revised28 Nov 2010
Accepted02 Dec 2010

Abstract

The clinical outcome of the traditional adoptive cancer immunotherapy approaches involving the administration of donor-derived immune effectors, expanded ex vivo, has not met expectations. This could be attributed, in part, to the lack of sufficient high-avidity antitumor T-cell precursors in most cancer patients, poor immunogenicity of cancer cells, and the technological limitations to generate a sufficiently large number of tumor antigen-specific T cells. In addition, the host immune regulatory mechanisms and immune homeostasis mechanisms, such as activation-induced cell death (AICD), could further limit the clinical efficacy of the adoptively administered antitumor T cells. Since generation of a sufficiently large number of potent antitumor immune effectors for adoptive administration is critical for the clinical success of this approach, recent advances towards generating customized donor-specific antitumor-effector T cells by engrafting human peripheral blood-derived T cells with a tumor-associated antigen-specific transgenic T-cell receptor (TCR) are quite interesting. This manuscript provides a brief overview of the TCR engineering-based cancer immunotherapy approach, its advantages, and the current limitations.


More related articles

 PDF Download Citation Citation
 Order printed copiesOrder
Views491
Downloads1065
Citations

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.